October 2026
Spravato is FDA-approved esketamine nasal spray for adults with treatment-resistant depression. It is not taken home. Under the REMS program it is self-administered only in a certified clinic, then followed by on-site monitoring. That is different from IV ketamine, which is a different route and is used off-label for depression. Neither is a cure, and neither is automatically better than the other.
A 2025 review in Neuropsychiatric Disease and Treatment summarized trials of intranasal esketamine, including TRANSFORM-2, SUSTAIN-1, and ASPIRE. Those studies are often cited for rapid antidepressant effects, often within hours, through NMDA receptor antagonism. Side effects discussed in the literature include dissociation and blood pressure changes, which is why the observation window exists. This is a research summary, not a promise about any one person.
How Spravato REMS works
REMS means the medicine is restricted to certified sites. At Rewired Ketamine in Aventura, Spravato is given in the office under observation. You stay for monitoring after the dose. Visits are scheduled, not mailed. A consult and medical screening decide whether it is appropriate.
Spravato vs IV ketamine
People comparing Spravato and IV ketamine are usually asking about setting, monitoring, and insurance. Spravato is a branded nasal spray given under REMS. IV ketamine is an infusion, also given in clinic, with a different dosing and recovery pattern. We offer both. The right fit is decided after a consult, not by a headline.
Spravato in Aventura, serving Miami
Rewired Ketamine is a locally owned, REMS-certified clinic in Aventura. Patients searching Spravato Aventura or esketamine Miami are usually looking for an in-person visit in the North Miami metro. We serve Miami, Fort Lauderdale, and South Florida. ¡Hablamos Español!
Details on visits, monitoring, and insurance are on our Spravato page. Depression care is described on depression. A free consult is the place to ask which option, if either, fits.
Source: Raza et al., Neuropsychiatric Disease and Treatment, 2025;21:2125–2140. DOI 10.2147/NDT.S548944.
